Giant spider provides promise of pain relief for irritable bowel syndrome

September 20, 2020

Molecules from the venom of one of the world's largest spiders could help University of Queensland-led researchers tailor pain blockers for people with irritable bowel syndrome (IBS).

Researchers screened 28 spiders, with the venom of the Venezuelan Pinkfoot Goliath tarantula - which has a leg-span of up to 30 centimetres - showing the most promise.

The team led by Professor Richard Lewis from UQ's Institute for Molecular Bioscience in collaboration with Flinders University's Professor Stuart Brierley and the South Australian Health and Medical Research Institute hopes to find effective pain relief for chronic intestinal pain.

"All pains are complex but gut pain is particularly challenging to treat, and affects around 20 per cent of the world's population," Professor Lewis said.

"Current drugs are failing to produce effective pain relief in many patients before side effects limit the dose that can be administered." Professor Brierley said IBS and other gastrointestinal and bladder disorders cause chronic visceral pain - pain which affects the internal organs.

"Internal organs have a complex network of sensory nerves that have a wide array of voltage-gated ion channels and receptors to detect stimuli," he said.

"The hypersensitivity of these nerves in disease often contributes to the development of pain."

Voltage-gated ion channels open and close in response to changes across the cell membrane, with their dysfunction identified as a cause of chronic visceral pain.

Professor Lewis said spider venoms contain hundreds of mini-proteins known as peptides that can inhibit voltage-gated ion channels from opening.

"Unfortunately these peptides aren't completely selective for pain targets," he said.

"Our goal was to find more specialised pain blockers that are potent and target pain sodium channels for chronic visceral pain, but not those that are active in the heart and other channels."

The team found two peptides isolated from the tarantula venom inhibited the most important ion channels underlying pain, with one particularly potent at reducing the sensory nerves of the bladder and colon and nearly stopping chronic visceral pain in a model of IBS.

"We now have a really strong understanding of the structure and function of these spider venom peptides," Professor Lewis said.

"The highly selective ones have potential as treatments for pain, while others are useful as new research tools to allow us to understand the underlying drivers of pain in different diseases."
-end-
The research evolved from 15 years of studying the potential of medicines developed from venoms, was published in the journal Pain and funded by the National Health and Medical Research Council.

Video - https://youtu.be/8JsWRvaW5Jk

University of Queensland

Related Irritable Bowel Syndrome Articles from Brightsurf:

Giant spider provides promise of pain relief for irritable bowel syndrome
Molecules from the venom of one of the world's largest spiders could help University of Queensland-led researchers tailor pain blockers for people with irritable bowel syndrome (IBS).

An aspirin a day keeps the bowel doctor away
A regular dose of aspirin to reduce the risk of inherited bowel cancer lasts at least 10 years after stopping treatment, research has revealed.

Mindfulness program may benefit patients with irritable bowel syndrome
Adults with irritable bowel syndrome experienced fewer gastrointestinal symptoms after they participated in a mindfulness program meant to reduce stress.

The Lancet Gasteroenterology & Hepatology: First clinical trial finds probiotic treatment with dead bacteria is better than placebo at alleviating symptoms of irritable bowel syndrome
Probiotic bacteria that have been killed by heat can significantly improve symptoms of irritable bowel syndrome (IBS) compared to placebo, and are not associated with any safety risk, according to a new 12-week, randomized, double-blind, placebo-controlled clinical trial with 443 patients published in The Lancet Gastroenterology & Hepatology journal.

Are steroids used too much for patients with inflammatory bowel disease?
Steroid therapy is commonly used to treat acute attacks of the inflammatory bowel diseases ulcerative colitis and Crohn's disease; however, because it does not provide long-term benefits and it carries a risk of serious side effects, it should not be used to treat inflammatory bowel disease for more than three months.

New, noninvasive test for bowel diseases
Gut diseases such as inflammatory bowel disease (IBD) are increasingly prevalent worldwide, especially in industrialized countries.

HKBU discovers mechanisms underlying early life stress and irritable bowel syndrome
Researchers from Hong Kong Baptist University have found that the abnormal rise of a soluble protein called Nerve Growth Factor is a key factor linking early life stress to the development of irritable bowel syndrome.

Microbiome science may help doctors deliver more effective, personalized treatment to children with irritable bowel syndrome
To improve the treatment of children with irritable bowel syndrome (IBS), investigators have developed a sophisticated way to analyze the microbial and metabolic contents of the gut.

The Lancet Gastroenterology & Hepatology: Hypnotherapy could help relieve irritable bowel syndrome symptoms
Peer-reviewed / Randomised Controlled Trial / People Gut-directed hypnotherapy delivered by psychologists appears as effective in group or individual sessions, potentially offering a new treatment option for irritable bowel syndrome in primary and secondary care

Early source of irritable bowel syndrome discovered
Michigan State University scientists have identified an early cause of intestinal inflammation, one of the first stages of inflammatory bowel disease and irritable bowel syndrome, which afflict around 11 percent of the world's population.

Read More: Irritable Bowel Syndrome News and Irritable Bowel Syndrome Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.